MX350282B - Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas. - Google Patents

Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.

Info

Publication number
MX350282B
MX350282B MX2014003745A MX2014003745A MX350282B MX 350282 B MX350282 B MX 350282B MX 2014003745 A MX2014003745 A MX 2014003745A MX 2014003745 A MX2014003745 A MX 2014003745A MX 350282 B MX350282 B MX 350282B
Authority
MX
Mexico
Prior art keywords
influenza
virus
binding molecule
neutralizing activity
cell
Prior art date
Application number
MX2014003745A
Other languages
English (en)
Other versions
MX2014003745A (es
Inventor
Shin Jae Chang
Ki Sung Kwon
Kye Sook Yi
Hyun Joo Lee
Jae Won Jeon
Hwang Keun Jun
Min Seok Chang
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltrion Inc filed Critical Celltrion Inc
Publication of MX2014003745A publication Critical patent/MX2014003745A/es
Publication of MX350282B publication Critical patent/MX350282B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)

Abstract

La presente invención se refiere a una molécula de unión que tiene actividad neutralizadora del virus de la influenza A, derivado de una célula B humana, y la molécula de unión que tiene la actividad neutralizadora del virus de la influenza A, de acuerdo con la presente invención, es una molécula de unión que se deriva de una célula B que está seleccionada de la sangre de un paciente infectado con un virus de influenza A y tiene actividad neutralizadora contra el virus de la influenza A y, por lo tanto, es útil para prevenir y tratar enfermedades derivadas del virus de la influenza A y puede ser útil para diagnosticar el virus de la influenza A, usando la molécula de unión de acuerdo con la presente invención.
MX2014003745A 2011-09-30 2012-09-27 Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas. MX350282B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110099646 2011-09-30
PCT/KR2012/007835 WO2013048153A2 (ko) 2011-09-30 2012-09-27 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자

Publications (2)

Publication Number Publication Date
MX2014003745A MX2014003745A (es) 2014-07-22
MX350282B true MX350282B (es) 2017-09-01

Family

ID=47996632

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003745A MX350282B (es) 2011-09-30 2012-09-27 Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.

Country Status (12)

Country Link
US (2) US9475861B2 (es)
EP (1) EP2762491B1 (es)
JP (1) JP5998222B2 (es)
KR (1) KR101514682B1 (es)
CN (1) CN104011077B (es)
AU (1) AU2012316930B2 (es)
CA (2) CA2850720C (es)
EA (1) EA026527B1 (es)
ES (1) ES2641257T3 (es)
IL (1) IL231779B (es)
MX (1) MX350282B (es)
WO (1) WO2013048153A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
CN104892753B (zh) * 2014-03-07 2019-11-29 神州细胞工程有限公司 一种中和人感染h7n9甲型流感病毒的抗体及其用途
WO2016010160A1 (ja) * 2014-07-18 2016-01-21 国立感染症研究所長が代表する日本国 抗インフルエンザウイルス抗体及びその利用
US20180008702A1 (en) * 2014-12-05 2018-01-11 Celltrion Inc. Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
WO2016089181A1 (ko) * 2014-12-05 2016-06-09 (주)셀트리온 1 이상의 인플루엔자 바이러스 중화 결합 분자를 포함하는 애주번트 조성물 및 이를 포함하는 백신 조성물
US11135282B2 (en) * 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3419663A1 (en) 2016-02-24 2019-01-02 Visterra, Inc. Formulations of antibody molecules to influenza virus
CN110192096B (zh) * 2016-04-21 2022-04-19 艾珀尔有限公司 生物体物质检测用设备和检测装置、离子电流的测定方法以及生物体物质的识别方法
EP3498263B1 (en) * 2016-08-10 2023-11-29 Celltrion Inc. Stable liquid pharmaceutical preparation for anti-influenza virus antibody
KR102320280B1 (ko) * 2018-05-31 2021-11-29 주식회사 센트릭스바이오 CD300c의 발현 억제제 또는 활성 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
KR20200060969A (ko) 2018-11-23 2020-06-02 (주)셀트리온 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2637837A1 (en) 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
US8148085B2 (en) * 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
WO2007134327A2 (en) * 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
WO2009121004A2 (en) * 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
ES2662519T3 (es) 2008-07-25 2018-04-06 Institute For Research In Biomedicine Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos
CN102482345A (zh) * 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
ES2802623T3 (es) * 2010-01-27 2021-01-20 Massachusetts Inst Technology Agentes polipeptídicos técnicamente diseñados para la neutralización dirigida de amplio espectro de la gripe
US9573991B2 (en) * 2010-03-08 2017-02-21 Celltrion, Inc. Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses
EP2596017B1 (en) * 2010-07-22 2019-04-03 John W. Schrader Cross-protective antibody against influenza viral infection
US9469685B2 (en) * 2011-01-10 2016-10-18 Emory University Antibodies directed against influenza

Also Published As

Publication number Publication date
AU2012316930B2 (en) 2016-06-09
WO2013048153A3 (ko) 2013-05-23
KR101514682B1 (ko) 2015-04-23
CA2850720C (en) 2016-03-29
CN104011077A (zh) 2014-08-27
MX2014003745A (es) 2014-07-22
AU2012316930A1 (en) 2014-04-17
US20140234336A1 (en) 2014-08-21
EA026527B1 (ru) 2017-04-28
WO2013048153A2 (ko) 2013-04-04
EA201400274A1 (ru) 2014-09-30
JP5998222B2 (ja) 2016-09-28
EP2762491A4 (en) 2015-05-20
ES2641257T3 (es) 2017-11-08
US9856312B2 (en) 2018-01-02
EP2762491A2 (en) 2014-08-06
IL231779A0 (en) 2014-05-28
US20170037113A1 (en) 2017-02-09
US9475861B2 (en) 2016-10-25
EP2762491B1 (en) 2017-07-05
KR20130035916A (ko) 2013-04-09
JP2014530008A (ja) 2014-11-17
IL231779B (en) 2019-01-31
CA2900712A1 (en) 2013-04-04
CA2850720A1 (en) 2013-04-04
CN104011077B (zh) 2017-06-20

Similar Documents

Publication Publication Date Title
MX350282B (es) Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
DOP2014000170A (es) Compuestos de imidazopirrolidinona
MX360056B (es) Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
MX2011011331A (es) Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas.
CR20140410A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
MX346206B (es) Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b.
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
EA201400855A1 (ru) Моноклональные антитела человека, полученные из в-клеток человека и обладающие нейтрализующей активностью против вирусов гриппа а
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
BR112013020517A2 (pt) dispositivo de segurança
GT201500005A (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
BR112013020743A2 (pt) composições e métodos para a terapia e diagnóstico de influenza
UY32457A (es) Vacuna del virus del dengue inactivado
BR112015000685A2 (pt) método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza.
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
EA201290373A1 (ru) Синергическая противовирусная композиция и ее применение
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
ES2429422R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
UY35695A (es) Composicion para el tratamiento contra el envejecimiento de la piel
UY34841A (es) VIRUS INFECCIOSO DE SCHMALLENBERG DE cADN CLONADOS Y SUS USOS
CL2015001481A1 (es) Uso de extracto bacopa monnieri
BR112014028632A8 (pt) Composto, composição farmacêutica, e, método para preparar um composto

Legal Events

Date Code Title Description
FG Grant or registration